Analystreport

Acasti Pharma Inc (NASDAQ: ACST) had its price target lowered by analysts at Aegis from $3.00 to $2.15. They now have a "buy" rating on the stock.

Acasti Pharma, Inc. - Class A  (ACST) 
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: acastipharma.com/investors